Pharmacokinetics of Avenciguat in Severe Liver Impairment

Phase 1, open-label trial of avenciguat in Portal Hypertension (PH) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point up to 6 days and Maximum measured concentration of the analyte in plasma up to 6 days. Started May 2024; status: terminated.